Back to Search
IVAN MARQUES BORRELLO M.D.
M.D.
Medical Oncology Physician
NPI: 1992761050IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D47390(MD)ME158526(FL)
Education
VIRGINIA COMMONWEALTH UNIVERSITY, SCHOOL OF MEDICINE
Class of 1992
Research & Publications (20)
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
PMID 19556425·Blood·2009
3-trial
Lenalidomide in renal insufficiency--balancing the risks and benefits.
PMID 19120361·Br J Haematol·2009
8-other
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.
PMID 18593947·Cancer Res·2008
7-preclinical
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
PMID 18489989·Biol Blood Marrow Transplant·2008
3-trial
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
PMID 18261793·Leuk Res·2008
8-other
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
PMID 18063750·Blood·2008
7-preclinical
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
PMID 18172311·Cancer Res·2008
7-preclinical
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
PMID 19192067·J Peripher Nerv Syst·2008
8-other
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
PMID 17889355·Biol Blood Marrow Transplant·2007
2-rct
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
PMID 18032763·N Engl J Med·2007
3-trial
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
PMID 16339406·Blood·2006
7-preclinical
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
PMID 16168663·Semin Cancer Biol·2006
6-review
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
PMID 16545725·Biol Blood Marrow Transplant·2006
3-trial
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
PMID 17016559·J Clin Invest·2006
7-preclinical
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
PMID 17101732·J Exp Med·2006
7-preclinical
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
PMID 15753403·Cancer Res·2005
8-other
Immunotherapeutic approaches for hematologic malignancies.
PMID 15561691·Hematology Am Soc Hematol Educ Program·2004
6-review
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
PMID 15342423·Cancer Res·2004
7-preclinical
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
PMID 12766881·Biol Blood Marrow Transplant·2003
8-other
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
PMID 12406877·Blood·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2 TAMPA GENERAL CIR FL 3
TAMPA, FL 33606 - Phone
- (813) 844-7585
Quick Facts
- NPI
- 1992761050
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile